Intravitreal quantum dots for retinitis pigmentosa: a first-in-human safety study.
Timothy L JacksonNaresh MandavaHugo Quiroz-MercadoMatthew BenageJose Gerardo García-AguirreVirgilio Morales-CantonLuana WilburJeffrey OlsonPublished in: Nanomedicine (London, England) (2021)
Background: Studies indicate that electrical stimulation of retinitis pigmentosa (RP) retina is beneficial. Quantum dots (QDs) can convert light to electrical stimulus and therefore may have therapeutic potential for RP. Methods: This was an open-label, fellow eye-controlled, first-in-human safety study. Five adults with end-stage (arm A) and 15 with severe (arm B) RP received one or two intravitreal injections of 0.2 or 2μM cadmium/selenium 655 Alt QDs. Results: No adverse events were attributed to QDs. In arm A, median best corrected visual acuity was unchanged. In arm B, mean best corrected visual acuity improved from 6/398 to 6/177, versus 6/147 to 6/144 in the fellow eye. Conclusion: Intravitreal QDs can be safely administered to patients with RP. Vision appears to benefit and further validating studies are justified.